US009408823B2

(12) **United States Patent**
Nelson et al.

(10) **Patent No.: US 9,408,823 B2**
(45) **Date of Patent: *Aug. 9, 2016**

(54) **BENZONATATE MODIFIED RELEASE SOLID TABLETS AND CAPSULES**

(71) Applicant: **TRIS Pharma Inc.**, Monmouth Junction, NJ (US)

(72) Inventors: **Andrea Nelson**, Edison, NJ (US); **Quin-Zene Chen**, Belle Mead, NJ (US); **Harsh Mehta**, Monroe Township, NJ (US); **Yu-Hsing Tu**, West Windsor, NJ (US)

(73) Assignee: **Tris Pharma, Inc.**, Monmouth Junction, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 19 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/863,784**

(22) Filed: **Sep. 24, 2015**

(65) **Prior Publication Data**

US 2016/0008312 A1 Jan. 14, 2016

Related U.S. Application Data

(63) Continuation of application No. 14/282,058, filed on May 20, 2014, now Pat. No. 9,180,104, which is a continuation of application No. PCT/US2014/023106, filed on Mar. 11, 2014.

(60) Provisional application No. 61/872,019, filed on Aug. 30, 2013, provisional application No. 61/780,689, filed on Mar. 13, 2013.

(51) **Int. Cl.**

A61K 9/22	(2006.01)
A61K 31/245	(2006.01)
A61K 31/09	(2006.01)
A61K 9/24	(2006.01)
A61K 9/28	(2006.01)
A61K 45/06	(2006.01)
A61K 9/00	(2006.01)
A61K 9/20	(2006.01)
A61K 9/50	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 31/245*** (2013.01); ***A61K 9/0053*** (2013.01); ***A61K 9/209*** (2013.01); ***A61K 9/2009*** (2013.01); ***A61K 9/2054*** (2013.01); ***A61K 9/2077*** (2013.01); ***A61K 9/2081*** (2013.01); ***A61K 9/2846*** (2013.01); ***A61K 9/2866*** (2013.01); ***A61K 9/2886*** (2013.01); ***A61K 31/09*** (2013.01); ***A61K 45/06*** (2013.01); *A61K 9/2013* (2013.01); *A61K 9/5084* (2013.01)

(58) **Field of Classification Search**

CPC A61K 9/2013; A61K 9/254; A61K 9/251; A61K 9/209; A61K 9/5054; A61K 31/09; A61K 31/245

USPC 424/464–489

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,775,694	A	10/1988	Press et al.	
4,915,948	A	4/1990	Gallopo et al.	
5,401,512	A	3/1995	Rhodes et al.	
6,423,339	B1	7/2002	Spireas	
6,793,934	B1 *	9/2004	Burnside	A61K 9/143 424/400
7,148,211	B2	12/2006	Mazess et al.	
8,062,667	B2	11/2011	Mehta et al.	
8,202,537	B2	6/2012	Mehta et al.	
8,202,542	B1	6/2012	Mehta et al.	
8,287,848	B2	10/2012	Mehta et al.	
8,287,903	B2	10/2012	Mehta et al.	
8,337,890	B2	12/2012	Mehta et al.	
8,357,398	B2	1/2013	Howard et al.	
8,465,765	B2	6/2013	Mehta et al.	
8,491,935	B2	7/2013	Mehta et al.	
8,512,688	B2	8/2013	Mehta et al.	
8,563,033	B1	10/2013	Mehta et al.	
8,597,684	B2	12/2013	Mehta et al.	
8,623,409	B1	1/2014	Mehta et al.	
2004/0265372	A1	12/2004	Wynn et al.	
2005/0137372	A1	6/2005	Kulkarni et al.	
2006/0141031	A1	6/2006	Nelson et al.	

(Continued)

FOREIGN PATENT DOCUMENTS

WO	WO 01/41737	A2	6/2001
WO	WO 04/000273	A1	12/2003
WO	WO 2008/089260	A2	7/2008
WO	WO 2012/054067	A1	4/2012

OTHER PUBLICATIONS

J.M. Huber Corporation, Zeopharm® 600 Product Specifications, revised Jun. 28, 2010.

BASF SE, "Benzonatate", Pharma Active Ingredients web page, http://product-finder.basf.com/group/corporate/product-finder/en/brand/BENZONATATE, accessed Dec. 19, 2014.

Evans et al., "Measurement of gastrointestinal pH profiles in normal ambulant human subjects", Gut, vol. 29(8):1035-1041, Aug. 1988.

Pfizer Inc., Tessalon®, 100 mg Perles 200 mg Capsules (Product Literature), revised Dec. 2015.

(Continued)

Primary Examiner — Micah-Paul Young

(74) *Attorney, Agent, or Firm* — Howson and Howson LLP; Egon Berg, Esq.; Cathy A. Kodroff

(57) **ABSTRACT**

A 12-hour anti-tussive modified release solid tablet or capsule is described which comprises a benzonatate adsorbate in a matrix with a sufficient amount of one or more pharmaceutically acceptable modified release pH-independent, substances to provide a 12-hour modified release profile to the benzonatate, wherein there is substantially no benzonatate release from the tablet or capsule in the buccal cavity and no more than about 25% release of the benzonatate within 1 hour as determined in an in vitro dissolution assay.

21 Claims, 1 Drawing Sheet